FDA Unlikely To Act Unilaterally To Increase ClinicalTrials.gov Postings
Executive Summary
FDA believes it has the authority to independently post clinical study information on ClinicalTrials.gov, but does not plan to create a systematic process for increasing the number of industry-sponsored trials listed on the site
You may also be interested in...
FDA Delays ClinicalTrials.gov Report To Include Additional Oncology Studies
FDA will include three additional months of oncology study listings in its report on the ClinicalTrials.gov registry
FDA Delays ClinicalTrials.gov Report To Include Additional Oncology Studies
FDA will include three additional months of oncology study listings in its report on the ClinicalTrials.gov registry
ClinicalTrials.gov Compliance Will Improve, PhRMA Tells Rep. Waxman
Industry may need several years to come into complete compliance with ClinicalTrials.gov, the Pharmaceutical Research & Manufacturers of America indicated in a letter to Rep. Henry Waxman (D-Calif.)